 CARLSBAD, Calif., Oct. 17, 2021 PRNewswire -- Ionis Pharmaceuticals, Inc. NASDAQ: IONS partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen BIIB067, an investigational antisense medicine being evaluated for people with superoxide dismutase 1 SOD1 amyotrophic lateral sclerosis ALS. 